Asensus Surgical, Inc. (AMEX:ASXC) Q2 2023 Earnings Call Transcript

Asensus Surgical, Inc. (AMEX:ASXC) Q2 2023 Earnings Call Transcript August 10, 2023

Asensus Surgical, Inc. misses on earnings expectations. Reported EPS is $-0.09 EPS, expectations were $-0.08.

Operator: Good afternoon, and welcome to the Asensus Surgical Second Quarter 2023 Business and Financial Update Call. All participants will be in listen-only mode. [Operator Instructions] After today’s presentation, there will be an opportunity to ask questions. [Operator Instructions] Please note this event is being recorded. I would now like to turn the conference over to Mark Klausner. Please go ahead.

Mark Klausner: Good afternoon, everyone, and thank you for joining us for the Asensus Surgical second quarter 2023 business and financial update conference call. On the call with me today are Anthony Fernando, President and Chief Executive Officer; and Shameze Rampertab, Chief Financial Officer. Before we begin, I would like to caution listeners that certain information discussed by management during this conference call, including any guidance provided, are forward-looking statements covered under the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those stated or implied by our forward-looking statements due to risks and uncertainties associated with the Company’s business, including any geopolitical risk factors beyond our control.

The Company undertakes no obligation to update the information provided on this call or discussion of risks and uncertainties associated with the Asensus Surgical business. I encourage you to review the Company’s filings with the Securities and Exchange Commission, including the 2022 Form 10-K filed in March 2023 and the Form 10-Q expected to be filed later today and any other filings we make with the SEC. During this call, we will also present certain non-GAAP financial information related to adjusted net loss attributable to common stockholders and the adjusted net loss per share attributable to common stockholders. Management believes that these non-GAAP financial measures taken in conjunction with U.S. GAAP financial measures provide useful information for both management and investors by excluding certain non-cash and other expenses that are not indicative of the Company’s core operating results.

Management uses non-GAAP measures to compare our performance relative to forecast and strategic plans, to benchmark our performance externally against competitors, and for certain compensation decisions. Reconciliations from U.S. GAAP to non-GAAP results are presented in the tables accompanying our earnings release, which can be found in the Investor Relations section of our website. With that, it’s now my pleasure to turn the call over to Asensus Surgical’s President and Chief Executive Officer, Anthony Fernando.

Anthony Fernando: Thanks, Mark, and thank you, everyone, for joining us today. To kick off, I’ll provide an overview of our recent performance and key achievements, after which Shameze will detail our financial results. Next, I’ll update you on our priorities for the rest of 2023 before we open the line for questions. During the second quarter, we made good progress across all our key areas. Our focus remains on expanding the adoption of Senhance, driving broader utilization of our intelligent surgical unit or ISU, advancing our clinical body of evidence and refining our portfolio to further enhance the capability of Senhance. Looking ahead, we are excited about the future with plans in place for the development of our new Luna surgical system.

Procedure volumes remain a key factor in our ability to expand and optimize our digital surgery capabilities. As we continue to collect surgical data, our machine learning engine becomes more effective, allowing us to provide valuable clinical intelligence to surgeons through the ISU. During the second quarter, we continue to see robust positive trends, delivering 27% year-over-year growth and over 11% sequential growth, with over 1,000 Senhance procedures performed across a variety of specialties globally. Over the past quarters, we have maintained a consistent 10% sequential growth rate, reflecting our commitment to progress and stability. Another positive aspect of increased procedure volumes is the expansion of our clinical registry. Our trust registry now includes data from over 25,000 patients with a growing number of cases across gynecology, general surgery and urology, which has been aided by the continued expansion of sites participating in the registry.

The primary goal for this registry is to create a collection of intraoperative and 12-month post-operative follow-up data. This data will be used to support an increased number of quality clinical publications and contribute to our market development strategy. Moving to new program initiation. We initiated two new Senhance programs year-to-date. The first was Fukuoka Tokushukai Hospital in Kasuga City, which we highlighted in our previous earnings call. In Japan, our growth continues as we enter into agreements with prominent institutions. We are pleased with the positive momentum in the country and are looking forward to supporting further adoption in the region. The second is a leading U.S. hospital that has initiated the Senhance program exclusively within their pediatric surgery department, highlighting Senhance’s unique suitability of pediatric applications.

This marks an important milestone as this is the first system to be exclusively utilized by pediatric surgeons at a U.S. based hospital. We continue to be active at key industry meetings to generate excitement about Senhance, the ISU, and ultimately, Luna. In July, we participated in the Society of Robotics Surgery or SRS annual meeting held in Melbourne, Australia. SRS is a unique event, where all robotic surgical technologies from various specialties come together. During the event, we had several podium presentations and symposiums featuring both company representatives and surgeons providing an excellent opportunity to showcase the unique capabilities of Senhance, LUNA and the ISU. The substantial interest and engagement we received regarding ISU and LUNA were particularly encouraging and our presence at this event signifies our commitment to driving innovation in robotics and digital surgery.

Additionally, we attended the first joint meeting of the International Pediatric Endosurgery Group or IPEG and the European Society of Pediatric Endoscopic Surgeons or ESPES meeting. We hosted a number of key events, including our sponsored ESPES robotic master class, which allowed surgeons from around the globe to explore robotics in pediatric surgery. The master class received positive feedback and our hands on training sessions showcase the precision and efficiency of the Senhance system in pediatric procedure. After attending several of these conferences over the past few quarters, we’ve seen strong validation of Senhance’s potential amidst the influx of new systems planning to be on the market. Our understanding of market needs backed by real world experience and valuable user input sets us apart.

The unique offering of real time augmented intelligence has generated excitement from surgeons and hospital administrators alike and we are confident we hold an edge over future market interest. Turning to other recent developments. As we stated earlier, during the quarter, we made progress in expanding our presence in the pediatric space. Since having received FDA clearance in March 2023, we have seen strong interest from pediatric surgeons. Our efforts to develop pediatric specific real world data have shown promising results demonstrating the safety and feasibility of using Senhance in pediatric cases. The combination of Senhance’s features such as 3 millimeter instrumentation and haptic feedback along with the ISU’s clinical intelligence makes it highly effective for pediatric procedure.

We have obtained the necessary clearances and approvals, including CE Mark and FDA 510(k) clearance allowing us to support surgeons globally and improve outcomes. We continue to see increased interest in Senhance and the ISU for pediatrics and are committed to meeting the growing demand in the market. In conclusion, I’m happy with the progress we’ve made in the second quarter and our strategic positioning for long-term success. Now, I will hand over the call to Shameze, who will provide a financial update.

Shameze Rampertab: Thanks, Anthony. Turning to the second quarter, for the three months ended June 30th, 2023, the company reported revenue of $1.1 million, as compared to revenue of $1 million in the three months ended June 30th, 2022. Revenue in the second quarter of 2023 included $0.5 million in lease revenue, $0.3 million in instruments and accessories, and $0.3 million in services. For the three months ended June 30th, 2023, total operating expenses were $18.9 million, as compared to $18.2 million in the three months ended June 30, 2022. For the three months ended June 30th, 2023, net loss attributable to common stockholders was $20.7 million or $0.09 per share, as compared to a net loss attributable to common stockholders of $19.6 million or $0.08 per share in the three months ended June 30th 2022.

For the three months ended June 30th, 2023, the adjusted net loss attributable to common stockholders was $20.3 million or $0.09 per share, as compared to an adjusted net loss of $17.3 million or $0.07 per share in the three months ended June 30th, 2022. Adjusted net loss is GAAP net loss adjusted for the following items: amortization of intangible assets, change in fair value of contingent consideration, and impairments of property and equipment, all of which are non-cash charges. Adjusted net loss attributable to common stockholders is a non-GAAP financial measure. Reconciliation from GAAP to non-GAAP measures can be found in our earnings release. Turning to the balance sheet, the company had cash, cash equivalents, and short term investments, excluding restricted cash of approximately $40 million as of June 30th, 2023.

In July, subsequent to the end of the second quarter, we completed a registered direct offering bringing in gross proceeds of approximately $10 million. We plan to allocate these funds to reinforce our working capital and contribute to research and development. Based on the recent financing and our current operating plan, we project our cash runway has been extended through late second quarter of 2024. I’ll turn the call back over to Anthony.

Anthony Fernando: Thank you, Shameze. Turning to the balance of 2023 and what we expect to achieve during the back half of the year. With regard to the LUNA program, we have made significant progress in R&D and are now focused on testing and evaluation ahead of preparing for regulatory filings in 2024. By the end of the third quarter 2023, we intend to complete full system integration and system testing and finalize our manufacturing strategy. Preclinical evaluation, which includes surgeons performing several procedures with the LUNA system on a [Indiscernible] model is scheduled for completion by the end of fourth quarter of this year. Looking ahead beyond 2023, Our plan is to freeze the systems designed in Q1 of 2024, conduct verification and validation testing, and ramp up pilot manufacturing.

By the end of 2024, we aim to submit to the FDA and other regulatory bodies in Europe and Japan. With the expectation of receiving FDA clearance in mid-2025. Following this milestone, we will proceed with a commercial pilot launch during the second-half of 2025. As it relates to our LUNA go-to-market efforts, two key advantages I would like to highlight. First, we believe that we have a clear regulatory pathway outlined for LUNA. In the U.S., based on our continued communications with the FDA, significant in-house regulatory expertise and our series of successful regulatory submissions for Senhance, we expect to be able to leverage a time and cost effective traditional 510(k) pathway in the U.S. rather than a more intensive de novo pathway.

We believe this streamlined regulatory strategy applies not only to the United States, but also to the European Union, Japan, and other parts of the world. This derisked regulatory process will significantly contribute to time to market advantages, compared to other new entrants to this space. This approach positions us favorably for expanding LUNAs market presence globally. Second, we believe LUNAs disruptive economic model, which when combined with the platform’s innovative clinical performance, will allow us to drive strong commercial adoption. In addition to our current leasing model and capital purchase model, there is the potential for LUNA to be available to hospitals through a subscription based model. This innovative approach aims to provide a greater level of economic flexibility for our customers offering increased accessibility they are by paving the way for broader adoption of the LUNA system without a significant increase in procedure cost, compared to laparoscopy.

Turning to ongoing ISU development efforts. We anticipate reaching two milestones during 2023. The first being entering into an agreement with a strategic graphics hardware provider in the second-half. And second, to finalize and ramp up pilot manufacturing for the future ISU by the end of the fourth quarter. These developments are crucial steps in advancing our LUNA program and expanding our digital capabilities with the ISU. As it relates to Senhance, we continue to expect to initiate 10 to 12 new programs throughout 2023. Additionally, we are optimistic that procedure volume growth will follow a similar trajectory as seen in the first and second quarter of the remainder of this year. The data collected from these procedures has been crucial and we anticipate even more valuable insights as additional sites adopt the ISU in the coming months.

Lastly, we are excited to make progress with LUNA, particularly in the preclinical evaluation, which we aim to complete by year-end. These are exciting times at Senhance. We have continued to push the boundaries of what is possible in robotics and digital surgery. And we will keep pushing to deliver the tools and capabilities that surgeons need to deliver better, more consistent outcomes for their patients. With that, I would like to open the line for questions.

See also 25 Best Work from Home Jobs for 2023 and 20 Countries with the Best Economy in the World.

Q&A Session

Operator: We will now begin the question-and-answer session. [Operator Instructions] First question comes from RK at H.C. Wainwright. Please go ahead. Mr. Ramakanth.

RK Ramakanth: Thank you. this is RK from H.C. Wainwright. good afternoon, Anthony and Shameze. So, couple of questions from me. Certainly, it’s really encouraging to see the 11% sequential growth in the procedure volume and also seeing that, you know, you are growing at least 10% quarter-over-quarter for three quarters now. what is driving that growth and, you know, what have either you when I say you, what is [Indiscernible] done to assure yourselves that sustained growth of 10% and above?

Anthony Fernando: Hi, RK. Thanks for the question. So I think the how we see this is the more familiarity that the hospitals gain. And also, when they gain familiarity, as you know, when we start, we start with a few number of surgeons and once time passes, there are more surgeons that — at the same hospital, that try to use the system. So the procedures have been growing. So that’s one area that we’ve seen growth coming from existing hospitals, you know, doing more cases with the additional surgeons. And the second is, you know, as you remember, you know, at the back half of last year, we placed a significant amount of systems, majority were placed in the second-half. So that also is playing in now because they’ve done the installations and getting up to speed and coming up their learning curve.

So they have begun to produce. So I think those are the two factors that are continuing to contribute. And, you know, when you look at it on a year-to-date basis, you know, we have grown procedure volume 27%, compared to last year and I think that’s kind of what we think we can continue given these two factors coming together.

RK Ramakanth: Thanks for that. And in terms of the installations itself, you know, as you said, we’ll — for the last couple of years at least, we have been watching more installations happen in the second-half rather than in the first-half. And it probably is going to be the same situation this year? What drives it to be a second-half event? You know, is it because, these things take a longer sales cycle. And I know, you know, you doesn’t have to be an outright sale anymore. You know, you folks are — have a subscription — the lease model, which helps, but still, it seems like, you know, it is taking a bit long. I’m not saying a bit longer, but longer. And I’m just trying to understand the dynamics of the sales cycle?

Anthony Fernando: Yes. Sure, RK. So, again, I think the, you know, it is the interest and the pipeline exists. It is trying to convert the pipeline into a play, you know, placement of a system, whether it’s a sale or operating lease. And that decision, you know, economics is one part of that decision, but also the hospital and the staff, they also have to be ready and trying to, you know, be willing to do their training, get up to speed and start using the system. So, it is — I know just looking at the last year and this year it’s beginning to see like somewhat of a pattern, but it’s — it takes time and it is continuing to take time for the hospitals to come to that decision to say, okay, now let’s start this program. But from a pipeline point of view, I can say that, you know, we feel very bullish about the pipeline and know that we can, you know, deliver on that this commitment of 10 to 12 systems, but the decision cycle is a long one, because hospitals are doing the diligence and, trying to get as much consensus internally as they can with surgeons, so that they can make the program successful.